ITEM 1. BUSINESS

The Corporation

Mymetics Corporation is a holding company conducting business through its subsidiaries 6543 Luxembourg S.A., a joint stock company organized in 2001 under the laws of Luxembourg ("LuxCo"), and Mymetics S.A. (formerly Hippocampe S.A.), a company organized in 1990 under the laws of France ("Mymetics S.A."). Mymetics Corporation was incorporated in July 1994 pursuant to the laws of the Commonwealth of Pennsylvania under the name "PDG Remediation, Inc." In November 1996, the Corporation reincorporated under the laws of the State of Delaware and changed its name to "ICHOR Corporation." In July 2001, the Corporation changed its name to "Mymetics Corporation." LuxCo is a majority-owned subsidiary of Mymetics Corporation and Mymetics S.A. is a 99.9%-owned subsidiary of LuxCo. In this document, unless the context otherwise requires, "Mymetics" and the "Corporation" refer to Mymetics Corporation and its subsidiaries.

Development of the Corporation

From its inception in 1994 to December 1997, the Corporation operated in the environmental services industry, focusing on thermal treatment (in Florida), remediation services (in Florida and Pennsylvania) and waste oil recycling (in Illinois). In February 1995, the Corporation completed an initial public offering. In 1998 and 1999, after disposing of its thermal treatment, remediation services and waste oil recycling businesses, the Corporation provided consulting services to an industrial customer in Europe. In June 1999, the Corporation acquired a majority interest in Nazca Holdings Ltd., whose business involved the exploration for and development of groundwater resources in Chile. Following the Corporation's disposal of its interest in Nazca in July 2000, the Corporation did not have an operating business.

In March 2001, Mymetics acquired substantially all of the shares of Mymetics S.A. in consideration for shares of common stock of Mymetics and shares of preferred stock of LuxCo, which are convertible into shares of common stock of Mymetics. Prior to the share exchange, Mymetics S.A. was a biotechnology research and development company.

On June 30, 2001, the Corporation closed on a private offering of 1,333,333 shares of its common stock, at E1.77 per share, for an aggregate price of E2,355,600 (net of offering expenses). This private placement was exempt from registration pursuant to Regulation S of the Securities Act of 1933, and the shares were sold to foreign investors meeting the requirements of Regulation S.

Mymetics S.A.

Mymetics S.A. is a biopharmaceutical company devoted to fundamental and applied research in the area of human and veterinary biology and medicine. Mymetics S.A.'s primary objective is to develop therapies to treat certain retroviruses, including the human immunodeficiency virus ("HIV"), the virus that leads to acquired immunodeficiency syndrome ("AIDS"). Additional applications of Mymetics S.A.'s research include potential treatments and/or vaccines for animal AIDS, human and animal Oncoviral Leukemias, multiple sclerosis and organ transplantation. To date, Mymetics S.A. has conducted its fundamental research in Europe.

Mymetics S.A. intends to form a new United States subsidiary during the second quarter of 2002. This new subsidiary will focus on applying our research and development to target products and on business development. Mymetics S.A. believes that this tiered structure has numerous advantages, including greater access to grants, subsidies, intellectual property and public and private research teams. To date, activities such as design of the prototype molecule, synthesis and in vitro experiments have been and will continue to be conducted mainly in Europe, while pre-clinical studies, toxicological trials, regulatory affairs, IND, Phase I, II, III, and NDA will, after the creation of the United States subsidiary, be conducted mainly in North America.

Mymetics S.A.'s research strategy is to organize and manage a collection of public and private best-in-class research teams, each of which has its own unique focus. Mymetics S.A. has segmented its primary research into modules, which are then out-sourced, under

its direct supervision, to high-level, specialized and complementary public and private research teams. Mymetics S.A. retains all intellectual property rights on the combined research and applies for domestic and international patents whenever justified. As agreed and coordinated by Mymetics S.A., the research teams are authorized to co-publish their results.

Science Overview

Virus. A virus is a noncellular organism consisting of deoxyribonucleic acid ("DNA") or ribonucleic acid ("RNA") and a protein coat. During the free and infectious stage of their life cycle, viruses do not perform the usual functions of living cells, such as respiration and growth. Rather, when viruses enter a living plant, animal or bacterial cell, they utilize the host cell's chemical energy and synthesizing ability to replicate. After the replication of the viral components by the infected host cell, virus particles are released and the host cell is often destroyed. The approximately 2450 viral species identified to date are divided into about 75 groups. HIV belongs to the group of retroviruses, so called because they contain a reverse transcriptase that copies viral RNA back into DNA (the reverse of what usually occurs when DNA is copied into RNA). Retroviruses include spumaviruses, oncoviruses (causing cancers) and lentiviruses (viruses with a slow pathogenic action, e.g. AIDS-associated lentiviruses).

HIV. HIV is a type of retrovirus, a virus of the family Retroviridae that has RNA as its nucleic acid and uses the enzyme reverse transcriptase to copy its genome into the DNA of the host cells chromosomes. Once inside the T cell, HIV uses the cell's machinery to copy its RNA into DNA by means of the reverse transcriptase. HIV is characterized by an inability to mount a normal immune response and is responsible for the fatal illness known as AIDS. AIDS is the late stage of infection caused by the HIV virus.

Two strains of HIV have been identified, HIV-1 and HIV-2. The genetic material of these two strains is approximately 60% identical. Each strain contains a number of subtypes, which are slight genetic variations of the virus. At least 32 sub-types have been identified to date. These variations result from the high mutation rate of HIV's genetic material. Most variations occur in the gene encoding the GP120 protein, and these mutations can alter the protein's structure. HIV-1 or Type 1 classified as a lentivirus is a subgroup of retroviruses that have been isolated and recognized as the cause of a disease that induces AIDS. HIV-1, like most viruses and all bacteria, plants and animals, has genetic codes made up of DNA, which uses RNA to build specific proteins. HIV's genetic material is the RNA itself. HIV inserts its own RNA into the host cell's DNA, preventing the host cell from performing its natural functions and transforming it into an HIV virus factory.

AIDS. AIDS is a fatal epidemic disease caused by an infection by HIV (HIV-1 or HIV-2). In most cases, HIV slowly attacks and destroys the immune system, the body's defense against disease, leaving the infected individual vulnerable to malignancies and infections that eventually cause death. Propagation of the HIV virus results from the invasion of the host cell and its use of the host cell's protein synthesis capability. The immune system's response (antibodies and cellular immune response) is usually sufficient to temporarily arrest progress of the infection and reduce levels of the virus in the blood. Virus replication continues, however, and gradually destroys the immune system by infecting and destroying critical white blood cells known as CD4 cells. The main cellular target of HIV is a special class of white blood cells critical to the immune system, known as helper T lymphocytes, or T4 helper cells. These cells play a principal role in normal immune responses by stimulating or activating virtually all of the other cells involved in immune protection. These cells include B lymphocytes, the cells that produce antibodies needed to fight infection; cytotoxic T lymphocytes, which destroy cells infected with virus; and macrophages and other effector cells, which attack invading pathogens. Once HIV has entered the helper T cell, it can impair the functioning of or destroy the cell. A hallmark of the onset of AIDS is a drastic reduction in the number of helper T cells in the body. HIV also can infect other cells, including certain monocytes and macrophages, as well as brain cells. Among those cells are CDA, HIV's preferred target cells due to a docking molecule called cluster designation 4 ("CD4") on their surfaces. Cells with this molecule are known as CD4-positive ("CD4+") cells. These cells normally orchestrate the immune response, signaling other cells in the immune system to perform their special functions. Destruction of CD4+ lymphocytes is the major cause of the immunodeficiency observed in AIDS, and decreasing CD4+ lymphocyte levels appear to be the best indicator of morbidity in these patients. As the infection progresses, the immune system's control of HIV levels weakens, the level of the virus in

the blood rises and the level of critical T cells declines to a fraction of their normal level.

Viral Envelope of HIV. The viral envelope of HIV is covered with mushroom-shaped spikes that enable the virus to attach itself to the target cell. The cap of each "mushroom" is comprised of GP120 molecules and its stem is comprised of GP41 molecules. GP120 is a glycoprotein that protrudes from the surface of HIV and binds to the CD4 receptor of the CD4+ T-cells. In a two-step process that allows HIV to breach the membrane of T-cells, the GP120-CD4 complex refolds to reveal a second structure that binds to CCR5 or CXCR4, one of several chemokine co-receptors used by the virus to gain entry into T cells. GP41 is a glycoprotein embedded in the outer envelope of HIV and plays a key role in HIV's infection of cells by carrying out the fusion of the viral and cell membranes. GP160 is a glycoprotein, which is the precursor of HIV envelope proteins GP120 and GP41.

Immune System. The immune system functions to protect the body against infection and foreign substances, including viruses and bacteria. This defensive function is performed by the body's white blood cells (leukocytes) and by a number of accessory cells, including B lymphocytes, the cells that produce the antibodies needed to fight infection, and cytotoxic T lymphocytes, which destroy cells infected with viruses. When an immunocompetent cell recognizes foreign material or a biological invader presented by the macrophages, it normally induces a response. This recognition function relies on the immune system's ability to recognize specific foreign molecular configurations, generically referred to as antigens. T4 lymphocytes, as the central cells of the immune system, specifically recognize foreign invaders presented by macrophages. After specific recognition of a presented antigen, T4 lymphocytes play a major role in the immune response, producing interleukine-2 ("IL-2"), a central interleukine that activates all of the accessory cells previously described and the overall immune response.

Mymetics S.A.'s Focus and Competitive Advantages

Mymetics S.A.'s current objective is to develop a platform of both therapeutic compounds and vaccines. Mymetics S.A. has made a series of discoveries about how the body's immune system responds to retroviruses, specifically HIV. The foundation of Mymetics S.A.'s platform technology and product pipeline is its discovery of a subtle mimicry between the virus and the host cells. By understanding the precise dynamics of the virus's GP41 and the host-cell's IL-2, Mymetics has illuminated the path to designing specific therapeutic molecules and antibodies to disrupt or even prevent the disease. Equally important, Mymetics S.A. plans to apply these findings to a range of additional diseases, including certain oncoviruses like leukemia.

Current approaches to treating HIV focus on slowing or impeding the progress of the virus once it has infected the body's host cells. Other biotechnology firms are attempting to develop therapies that prevent the virus from fusing with host cells. If the virus cannot fuse, it cannot reproduce, and the body's immune system then succeeds in arresting the invasion. Mymetics S.A.'s approach is also based on the concept of preventing viral fusion. Mymetics S.A.'s scientific strategy is unique in that its design is based on a series of discoveries involving mimicry, and, in particular, on the inter-reaction between the viral envelope glycoprotein ("GP41") and the host cell's IL-2. Mymetics S.A. has discovered that a piece of the virus closely resembles or "mimics" the host cell's IL-2. By exploiting this mimicry, the virus unlocks the host cell and gains access to the cell's machinery. The immune system responds to the invasion, but fail to differentiate between the viral GP41 and the host cell's IL-2. As a result, we believe that the immune system attacks both of them with equal vigor. The unfortunate consequence is that the body, in turning on itself, undercuts its own defenses. By understanding these precise dynamics, Mymetics, S.A. has illuminated the path to designing specific therapeutic molecules and antibodies to disrupt the mimicry. The current scientific strategy is to create therapeutic peptides and antibodies to disrupt the mimicry, block the fusion, and "train" the body's immune system to recognize GP41 as separate and distinct from IL-2.

The Discovered Molecular Mimicry Between Trimeric GP41 AND IL-2 - A Closer Look. Mymetics S.A. discovered a molecular mimicry between the trimeric ectodomain of the transmembrane protein of immunosuppressive lentiviruses (HIV-SIV-FIV) and IL-2. Mymetics S.A.'s initial results were communicated by Pr. Luc Montagnier to the French Academy of Sciences, and published in November 2000. (Note that Pr. Luc Montagnier is not an affiliate of the Corporation.)

It was Pr. L. Montagnier, of the Institut Pasteur in Paris, who discovered the HIV virus in 1983. Mymetics S.A. has further proven that the aforementioned mimicry exists in three mammal species known to be "AIDS prone," - man, monkeys and felines. The discovered host-virus autoimmune mimicry is therefore universal and applies to all human and animal AIDS-associated retroviruses.

Autoimmune Consequences For HIV Infected Subjects. Mymetics found some of the expected autoimmune consequences of the described virus-host molecular mimicry in HIV infected subjects. As expected, HIV positive sera recognize human IL-2, and cross-reactivity was found between the structurally and physically antigenic analogous sites of GP41 (HIV-1) and human IL-2. The tests included 2352 HIV+ and HIV-sera, and the results demonstrated that 100% of HIV+ patients (stages II, III and IV) were positive for the anti IL-2 response.

The first results were presented in a Symposium organized by the Merieux Foundation and entitled "Autoimmunity induced by infection or immunization". The title of the presentation by Pierre-Francois Serres, Chief Scientific Officer of the Corporation, was "AIDS: an immune response against the immune system; The role of a precise tridimensional molecular mimicry." These results were published in the Journal of Autoimmunity in 2001 and were also presented in a poster session at the Cold Spring Harbor, NY meeting on infectious disease in December 2000.

Therapeutic and Vaccinal Use of the Mimicry Discovery

Mymetics S.A.'s current research modules focus on the following four fields:

- Fundamental research. Mymetics S.A. believes that its insight into the GP41/IL-2 mimicry can explain, in large part, the main AIDS-associated disorders: drop of peripheral IL-2, decrease of non-infected T helper lymphocytes, lymphoproliferation disorders and a2 microglobulin increase and hypergammaglobulinemia. Some of the possible effects of the tridimensional GP41 (HIV-1)/human IL-2 molecular mimicry on the AIDS-associated disorders are being evaluated by Mymetics S.A.'s research teams.

- Therapeutic molecules. Mymetics S.A. believes that, based on the mimicry, an application involving the development of particular synthetic peptides and monoclonal antibodies (some of which have already been developed) would inhibit the fusion between the HIV virus and its target cell in an infected subject. Well-designed therapeutic molecules would prevent the virus from binding to the target cell, inhibiting its attempts to reproduce. Having demonstrated that the transmission of HIV depends on the viral load, and that no transmission has been observed below 1500 viral copies/ml., treatment with therapeutic agents may provide a strategy to control AIDS epidemicity. This application would complement available antiretroviral drugs, or may even provide a substitute for the available antiretroviral drugs.

- Therapeutic and preventive vaccines. Mymetics S.A. believes that its discovery of the host-virus autoimmune mimicy opens the door to novel therapeutic and preventive vaccine strategies for both humans and animals. Mymetics S.A. believes that its specific preventive vaccine would be universal for both HIV-1 and HIV-2, and would provide an all-strain prevention.

- AIDS Cartridge. Mymetics S.A. has developed a number of therapeutic immunocartridges that would help patients infected with AIDS by reducing the viral load. These immunocartridges have been tested and approved by the Ethics Committee for the Treatment of Systemic Lupus Erythematosus and Hemophilia A. Mymetics S.A.'s research has demonstrated that the anti IL-2 antibodies in HIV infected subjects recognize some sites of IL-2 that are crucial for its bioactivity. Therefore, Mymetics believes that the development of an "AIDS cartridge" could be efficient in the restoration of the immune system (CD4/CD8-viral load) of HIV infected subjects.

Products and Processes In Development. Four of Mymetics S.A.'s prototypes capable of commercialization include:

- Therapeutic molecules (pharmacological agents) - administered to infected subjects to prevent cell infection by the HIV virus.
- Therapeutic vaccines (immunotherapeutic agents) - administered to infected subjects to orient the immune system into recognizing the transmembrane glycoprotein of the virus and not the host's IL-2.

- Preventive vaccines - administered to healthy subjects to prevent infection by the HIV virus.
- AIDS cartridge - administered to infected subjects to selectively remove the identified immunosuppressive antibodies present in the serum of AIDS patients, using some peptides that have been tested for activity.

Key Staff

Peter P. McCann, Ph.D., a senior corporate executive and research scientist with 25 years of experience in the pharmaceutical and biotech industry, was named President and Chief Executive Officer and appointed to the Board of Directors of Mymetics Corporation in February 2002. Dr. McCann initially joined Marion Merrell Dow Inc., where he served in a number of senior executive capacities. He then served as President of British Biotech Inc., the North American operating unit of British Biotech Pharmaceuticals (the largest biotech company in Europe) from 1993-1998. In this capacity, he established British Biotech Inc. in Annapolis, Maryland, where he directed the company's phase II and phase III clinical trials of two major cancer drugs at more than 200 medical centers in the United States and Canada. Dr. McCann served as Interim President of the University of Maryland Biotechnology Institute, one of the 13 operating units of the University System of Maryland, from 1998-1999. From 1999-2001, Dr. McCann served as President and Chief Executive Officer of Oncostasis, Inc., a genomics-based cancer therapeutics company created to identify and develop new therapies. Dr. McCann entered into an employment agreement with the Corporation on March 18, 2002.

Joseph D. Mosca, Ph.D., an experienced research and development scientist in the field of immunology and AIDS virology, was named Vice President of Development of Mymetics Corporation in March 2002. Dr. Mosca joined the faculty of the Johns Hopkins University in 1982 and, subsequently, the staff of the Henry M. Jackson Foundation in Rockville, Maryland in 1989. From 1996 to 2000 Dr. Mosca held a number of management positions at Osiris Therapeutics in Baltimore, Maryland, the last of which was Director of Gene Delivery. Most recently he served as Executive Director of Research at Stemron Corporation in Gaithersburg, Maryland.

For the year ended December 31, 2001, Mymetics S.A. was focused on research and development and, as a result, did not generate any revenues or engage in any marketing activities. For the year ended December 31, 2001, Mymetics S.A. spent E482,000 on research and development activities.

Intellectual Property

The Corporation's policy is to extensively protect its technology products and processes pursuant to base and application patents filed in the United States, Europe and selected other countries.

Competition

Mymetics S.A. has not yet developed an actual product or generated any revenues. Mymetics S.A.'s future competitive position depends on its ability to successfully develop its intellectual property, and to either use such intellectual property to produce one or more products that can generate significant revenues or license such intellectual property to third parties on financially favorable terms. While we believe that the results of Mymetics S.A.'s research and development activities have been favorable, there are numerous entities and individuals conducting research and development activities in the area of human and veterinary biology and medicine all of which could be considered competitors of Mymetics S.A.

Mymetics S.A. faces significant competition for some of its therapeutic compounds and for its preventive vaccines.

Therapeutic Molecules (pharmacological agents). The biopharmaceutical industry is intensely competitive, especially in the field of HIV. If Mymetics S.A. is successful in developing and proving its therapeutic agents, it will compete with existing developed and approved therapies. The FDA has approved sixteen antiviral drugs to treat HIV and AIDS, which fall into two categories depending on whether they target one or two viral enzymes: either HIV protease or reverse transcriptase ("RT"). RT drugs aim to block reverse transcriptases and prevent transcription of the virus' generic material from RNA to DNA. There are two classes of RT drugs: nucleoside analogues inhibitors and non-

nucleoside inhibitors. The approved nucleoside analogues inhibitors include drugs such as Retrovir (ziduvodine; AZT), Videx (didanosine; ddl), Hivid (zalcitabine; ddc), Zerit (stavudine; d4T), Epivir (larnivudine; 3TC), Combivir (ziduvodine + lamivudine), Ziagen (abacavir; ABC). These drugs are manufactured by companies such as Glaxo Wellcome Plc, Bristol-Myers Squibb Company, Roche Holding AG and BioChem Pharma Inc. The approved non-nucleoside inhibitors include drugs such as Viramuno (nevlrapine), Rescriptor (delavirdine), Sustiva (efavirenz; EFV) which are produced by Boehringer Ingelhelm Gmbh, Pharmacia & Upjohn Inc. and E. I. Du Pont de Nemours and Company. The objective of approved protease inhibitor drugs is to prevent the assembly of new virus particles. The approved protease inhibitors include drugs such as Invirase (saquinavir), Fortovase (saquinavir), Norvir (ritonavir), Crixivan (indinavir), Viracept (nellinavir) and Agenerase (amprenavir), which are manufactured by companies including Roche Holding AG, Abbot Laboratories, Merck & Co. Inc., Agouron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated and Glaxo Wellcome Plc.

Both HIV protease and RT drugs have demonstrated their efficacy in terms of HIV blood concentration and HIV-positive period and are used to slow the progression of the disease. Furthermore, efficacy has been higher with drug combinations. None of these drugs are, however, a cure and mutations of HIV's envelope produce viral strains resistant to both classes of drugs. These drugs also produce toxic side effects on the peripheral nervous system and gastrointestinal tract. Non-compliance on combination therapies and interruptions in dosing could have an effect on and trigger accelerated viral replication.

If successful in developing and validating its therapeutic molecules, Mymetics believes that there are significant existing and future markets for the treatment of HIV and AIDS. There can be no assurance that currently approved drugs or products developed in the future for the treatment of HIV/AIDS by Mymetics S.A.'s competitors (which may include Roche Holding AG, Abbot Laboratories, Merck & Co. Inc., Agouron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Glaxo Wellcome Plc, Bristol-Myers Squibb Company, Trimeris, Inc., Progenics, Inc., and BioChem Pharma Inc.) will not be effectively marketed and sold. Mymetics believes, however, that its unique approach and fundamental understanding of molecular mimicry will provide an advantage over existing competitors.

Therapeutic Molecules (immunotherapeutic agent). Mymetics believes that its targeted immunotherapeutic vaccines may be innovative within the field of therapeutic research related to AIDS.

Preventive Vaccines. Mymetics is conducting research aimed at developing of a universal preventive vaccine for the HIV-1 and HIV-2 viruses, which vaccine will provide protection against all viral strains.

The worldwide vaccine market is dominated by four large multinational companies:
Merck & Co., SmithKline Beecham Plc, Wyeth Lederle Vaccines & Pediatrics (a division of American Home Products Corporation), and Aventis S.A. Pasteur. Companies such as The Immune Response Corporation, VaxGen Inc., Trimeris, Inc., and Progenics Pharmaceuticals, Inc. are also developing preventive vaccines.

Mymetics S.A. believes that while these companies have greater financial, manufacturing, technical, human resource, marketing and distribution capabilities, and greater experience in conducting pre-clinical and clinical trials and in obtaining regulatory and Food and Drug Administration approvals, its technologies nonetheless provide a competitive advantage. Mymetics S.A.'s innovative approach to vaccine development is based on the observed immunological cross-reactivity (or mimicry) between the well preserved, antigenic and immunodominant domain of GP41 and IL-2, and relies on the observation of expected autoimmune consequences in HIV infected subjects.

Mymetics S.A. believes that its approach is most promising in comparison with the approaches that have been pursued so far, including:

- Sub-unit vaccine: a technology addressing a piece of the outer surface of HIV, such as GP160 or GP120, produced by genetic engineering.
- Live vector vaccine: a live bacterium or virus such as vaccinia (used in the smallpox vaccine) modified so it cannot cause disease, but can transport into the body one or more genes that makes one or more HIV proteins.

- Vaccine combination: an example includes a "prime-boost strategy", use of a recombinant vector vaccine to induce cellular immune responses followed by booster shots of a sub-unit vaccine to stimulate antibody production.
- Peptide vaccine: chemically synthesized pieces of HIV proteins (peptides) known to stimulate HIV-specific immunity.
- Virus-like particle vaccine (pseudovirion vaccine): a non-infectious HIV look-alike that has one or more, but not all, HIV proteins.
- DNA vaccine: direct injection of genes coding for HIV proteins.
- Whole-killed virus vaccine: HIV that has been inactivated by chemicals, irradiation or other means rendering it non-infectious.
- Live-attenuated virus vaccine: live HIV from which one or more apparent disease-promoting genes of the virus have been deleted.

Cartridge. Mymetics S.A. believes that its cartridge or therapeutic plasmapheresis is significantly different from the cartridges being developed and provided by competitors. The more specific technique for antibody removal is known as immunoadsorption, yet all existing systems are non-specific in removal of antibodies, which limits their effectiveness and may have serious side effects. Current immunoadsorption systems selectively remove antibodies by the interposition of affinity columns in the devices. These cartridges are expensive, large, require trained technicians and are not protein specific. In addition, the cartridge is based on a biocompatible membrane based on a discovery of antibody binding, which perform a highly specific extra-corporeal immunoadsorption. When specific (as compared with selective) there is the definitive advantage of removing only the targeted pathogenic antibodies while leaving the other antibodies essential to the patients normal immune systems, and defence against infection. The main competitor with respect to cartridges appears to be Aethlon Medical with its HIV Hemopurifier.

Governmental Regulation

The Corporation contracts with third parties to perform research projects related to its business. These third parties are located in various countries throughout Europe and are subject to the applicable laws and regulations of their respective countries.

As of December 31, 2001, Mymetics S.A. had seven full-time employees; Mymetics Corporation had one full-time employee.